Home Applications 216962 Application 216962
Type NDA
Sponsor ABBVIE Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 VYALEV FOSCARBIDOPA; FOSLEVODOPA SOLUTION;SUBCUTANEOUS 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N216962-001 VYALEV FOSCARBIDOPA; FOSLEVODOPA 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16
Orange Book patents# Current patent rows page 1 of 1 · 4 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 N216962-001 12251365 2040-06-10 U-4030 2025-04-10
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N216962-001 NP 2027-10-16
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 2680178bc6a6…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 d8e5a09893c0…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216962-001 VYALEV 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-10-16 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216962-001 12251365 2040-06-10 U-4030 2025-04-10 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216962-001 12251365 2040-06-10 U-4030 2025-04-10 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N216962-001 12251365 2040-06-10 U-4030 2025-04-10 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 2680178bc6a6…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216962-001 10174061 2035-10-21 U-4030 Drug product 2024-11-14 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216962-001 10730895 2035-10-21 Drug substance 2024-11-14 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216962-001 9446059 2035-10-21 U-4030 Drug substance, Drug product 2024-11-14 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216962-001 12251365 2040-06-10 U-4030 2025-04-10 a50c72e98297…
Observed Orange Book exclusivity history# Captured, Edition, Application-product table Captured Edition Application-product Exclusivity code Expiration Source SHA-256 2026-02-19 14:30 UTC 2026-02 N216962-001 NP 2027-10-16 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216962-001 NP 2027-10-16 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N216962-001 NP 2027-10-16 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216962-001 NP 2027-10-16 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216962-001 NP 2027-10-16 b8a1b40f171c…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216962-001 NP 2027-10-16 a50c72e98297…
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Vyalev FOSCARBIDOPA/FOSLEVODOPA AbbVie Inc. 28e806e4-951c-40a9-9f0c-d0929caf054c 2026-03-19 Warnings, Adverse reactions Exact identifier application applno (NDA): 216962 application number: NDA216962
Documents# Document, Submission type, Date table Document Submission type Date 85513 SUPPL 2026-03-24 85494 SUPPL 2026-03-24 85454 SUPPL 2026-03-23 82513 ORIG 2025-06-10 79942 ORIG 2024-10-21 79911 ORIG 2024-10-17